Faron Pharmaceuticals

0.49 EUR

-2.41 %

5,705 following
Corporate customer

FARON

First North Finland

Biotechnology & Pharmaceuticals

Health Care

-2.41 %
-11.80 %
-72.53 %
-75.65 %
-77.34 %
-79.07 %
-85.53 %
-86.77 %
-85.44 %

Faron is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments.

Read more
Market cap
98.68M EUR
Turnover
327.89K EUR
P/E (adj.) (26e)
-4.71
EV/EBIT (adj.) (26e)
-5.42
P/B (26e)
84.34
EV/S (26e)
25,763.13
Dividend yield-% (26e)
-
Coverage
Recommendation
Buy
Target price
0.75 EUR
Updated
11.03.2026
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 12.03.2026

Latest extensive report

Released: 23.08.2022

Revenue and EBIT-%

Revenue K

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
26.8
2026

Interim report Q2'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Forum discussions
If that previous partnership deal fell through due to the Verona results, then continuing cooperation negotiations with the same partner will very likely require preliminary data from this upcoming placebo-controlled trial. It will take time for these results to accumulate. Another...
13 hours ago
by jerej
40
2026 will be a gap year in terms of research results, and 2027 will likely be well underway before the first BEXMAB-2 results are obtained. Therefore, I don’t have much to comment on; those changes in ownership, etc., do not interest me. If you are looking for some “bearishness” ...
7 hours ago
by Clark kent
18
Someone recently asked for good news regarding Faron. I’ve tried to keep the “Faron-tinted glasses” on the shelf and gather clues about such things: Runway secured until 11/27 The scientific backing is becoming strong (I would mention J. Rannikko’s dissertation as part of this) Some...
15 hours ago
by Kulkuri
17
If only I dared to act like that. But what then? About 5-10% of the guesses regarding companies are correct, no doubt about it. I did participate in the share issue as well. People joke about long-term portfolios being the place where failed investments are moved. When you have enough...
5 hours ago
by Vino Pino
15
Did you bring up the Matins ORR figure just because it supports your narrative? Wasn’t the purpose of Matins to investigate safety and appropriate dosage? Furthermore, there were several dosage levels involved, all the way down to 0.1 mg/kg, which even the paper considers likely ...
3 hours ago
by Makkispekkis1
13
VinoPino has probably cashed out his Nokia shares and retired from this business, with the Faron losses written off as tax deductions (congratulations on the great profits!)
11 hours ago
by JusaVaan
10
I personally expect that this is the time for scientific evidence and results, which will then strengthen market confidence and, accordingly, spark the agreement and announcement of partnership and collaboration models.
14 hours ago
by Pekka
8
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.